Welcome to our dedicated page for enGene Therapeutics SEC filings (Ticker: ENGNW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on enGene Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into enGene Therapeutics's regulatory disclosures and financial reporting.
Cormorant Asset Management, LP and Bihua Chen have disclosed a significant passive stake in enGene Holdings Inc. common shares. They report beneficial ownership of 4,000,000 common shares, representing 5.97% of the class, held through certain Cormorant funds.
The percentage is calculated using 66,984,661 common shares outstanding as of December 17, 2025, as stated in enGene’s Form 10-K. All 4,000,000 shares are reported with shared voting and shared dispositive power, with no sole voting or dispositive power. The holding is certified as being in the ordinary course of business and not for the purpose of changing or influencing control of enGene.
Kynam Capital Management and related reporting persons disclose a 2.23% beneficial stake in enGene Holdings Inc. common shares on an amended Schedule 13G. They report beneficial ownership of 1,492,898 common shares, with shared voting and dispositive power and no sole voting or dispositive authority.
The filing names Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang as reporting persons and certifies the shares are held in the ordinary course of business, not for the purpose of changing or influencing control of enGene.
enGene Holdings Inc. reported a new equity award to its Chief Scientific Officer, Anthony Tzeyew Cheung. On January 30, 2026, he received a stock option to buy 195,000 common shares at an exercise price of $9.53 per share.
The option vests monthly in substantially equal amounts over 48 months, conditioned on his continued service. After this grant, he beneficially owns 195,000 derivative securities directly, aligning his compensation more closely with the company’s future share performance.
enGene Holdings Inc. reported a new stock option grant to its Chief Legal Officer and Corporate Secretary, Lee G. Giguere. On 01/30/2026, Giguere received a stock option for 195,000 common shares with an exercise price of $9.53, reported as held directly.
The option was granted at no cost and is structured to vest monthly in substantially equal amounts over 48 months, subject to Giguere’s continued service with the company. After this grant, Giguere beneficially owned 195,000 stock options tied to enGene common shares.
enGene Holdings Inc. granted a stock option to Chief Strategy & Ops Officer Alexander Julian Nichols covering 195,000 common shares on January 30, 2026.
The option has an exercise price of $9.53 per share and expires on January 30, 2036. It was granted at no cost to the reporting person and vests in substantially equal monthly installments over 48 months, conditioned on continued service. After this grant, Nichols beneficially owns 195,000 derivative securities directly.
enGene Holdings Inc. reported that Chief Financial Officer D. Ryan Daws received a new stock option grant. On 01/30/2026, he was awarded a Stock Option (Right to Buy) covering 220,000 common shares at an exercise price of $9.53 per share, for no upfront cost.
The option expires on 01/30/2036 and is held directly. It vests monthly in substantially equal amounts over 48 months, conditioned on his continued service with the company, so the right to purchase shares builds gradually over four years rather than all at once.
enGene Holdings Inc. CEO & President Ronald Harold Wilfred Cooper was granted a large stock option award. On 01/30/2026, he received a stock option covering 801,000 common shares at an exercise price of $9.53 per share. The option was reported as held directly.
The option vests monthly in substantially equal amounts over 48 months, conditioned on his continued service. After this grant, he beneficially owned 801,000 derivative securities tied to common shares through this option award.
enGene Holdings Inc. chief technology officer Joan Connolly received a stock option grant for 195,000 common shares on January 30, 2026. The options give her the right to buy these shares at an exercise price of $9.53 per share and expire on January 30, 2036.
The award vests monthly in substantially equal installments over 48 months, contingent on her continued service with the company. This Form 4 reports an incentive-based equity grant, with Connolly directly holding 195,000 derivative securities following the transaction.
enGene Holdings Inc. reported that Chief Regulatory Officer Boyd Matthew Ross received a grant of stock options on January 30, 2026. The award covers 195,000 stock options with an exercise price of $9.53 per common share and no upfront purchase price.
The options vest monthly in substantially equal installments over 48 months, as long as Ross continues his service with the company. Following this grant, Ross beneficially holds 195,000 derivative securities directly in the form of these options.
enGene Holdings Inc. disclosed that Chief Development Officer Jill Buck received a grant of stock options. On January 30, 2026, she was awarded 195,000 stock options with an exercise price of $9.53 per common share. These options were granted at no cost on the grant date and are held directly. The award vests monthly in substantially equal installments over 48 months, contingent on her continued service with the company, and represents her total reported derivative holdings after the transaction.